← Back to Clinical Trials
Recruiting NCT07241195

NCT07241195 A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07241195
Status Recruiting
Phase
Sponsor The Affiliated Hospital of Hangzhou Normal University
Condition NAFLD and NASH
Study Type OBSERVATIONAL
Enrollment 20,000 participants
Start Date 2026-03-12
Primary Completion 2030-12-31

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age 100 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20,000 participants in total. It began in 2026-03-12 with a primary completion date of 2030-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth from the aspects of lifestyle, environment and genetics, the development pattern and mechanism of fatty liver in the elderly will be analysed, and the health risk assessment system and Chinese standard for fatty liver in the elderly covering cardiovascular risk, risk of hepatic fibrosis and risk of sarcopenia will be established, so as to provide the scientific basis for the precise intervention of fatty liver in the elderly in China.

Eligibility Criteria

Inclusion Criteria: * ① Elderly people aged ≥65 years among permanent residents (living for more than 5 years) in the survey area; * Imaging diagnosis (ultrasound or FibroScan/FibroTouch) of fatty liver; -③ Voluntary participation in this study and signing an informed consent form. Exclusion Criteria: * ①Major disability, mental illness, major wasting disease, severe cardiac, pulmonary and renal insufficiency; * Patients with combined primary liver cancer or other types of cancer; -③Patients who have received liver transplant or other organ transplants.

Contact & Investigator

Central Contact

Wei Zhang, DR

✉ zhangwei969696@163.com

📞 +8613567135527

Frequently Asked Questions

Who can join the NCT07241195 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, up to 100 Years, studying NAFLD and NASH. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07241195 currently recruiting?

Yes, NCT07241195 is actively recruiting participants. Contact the research team at zhangwei969696@163.com for enrollment information.

Where is the NCT07241195 trial being conducted?

This trial is being conducted at Hangzhou, China.

Who is sponsoring the NCT07241195 clinical trial?

NCT07241195 is sponsored by The Affiliated Hospital of Hangzhou Normal University. The trial plans to enroll 20,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology